Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Sep;44(9):2593.
doi: 10.1128/AAC.44.9.2593-2593.2000.

Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir

X Duval, V Le Moing, C Longuet, C Leport, J L Vildé, C Lamotte, G Peytavin, R Farinotti

Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir

X Duval et al. Antimicrob Agents Chemother. 2000 Sep.
No abstract available

PubMed Disclaimer

References

    1. Adkins J C, Faulds D. Amprenavir. Drugs. 1998;55:837–842. - PubMed
    1. Adkins J C, Noble S. Efavirenz. Drugs. 1998;56:1055–1064. - PubMed
    1. Hsu A, Granneman R, Bertz R J. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35:275–291. - PubMed
    1. Livingston D J, Pazhanisamy S, Porter D J, Partaledis J A, Tung R D, Painter G R. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis. 1995;172:1238–1245. - PubMed
    1. Sadler B A, Hanson C D, Chittick G E, Symonds W T, Roskell N S. Safety and pharmakokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother. 1999;43:1686–1692. - PMC - PubMed

MeSH terms